Advance amount related to milestone payment.

No definition available.

Name:	LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Agreement for a term.

+ References

No definition available.

+ Details

Name:	LIXT_AgreementTermDescription
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount charge to operations.

+ References

No definition available.

+ Details

Name:	LIXT_AmountChargeToOperations
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company is obligated to pay annual license maintenance fee..

+ References

No definition available.

+ Details

Name:	LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Consulting and advisory quarterly cash fee.

+ References

No definition available.

+ Details

Name:	LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum amount received under agreement.

+ References

No definition available.

+ Details

Name:	LIXT_MaximumAmountReceivedUnderAgreement
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	LIXT_MilestonePayments
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Company is obligated to pay non refundable license issue fee..

+ References

No definition available.

+ Details

Name:	LIXT_NonRefundableLicenseIssueFee
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones.

+ References

No definition available.

+ Details

Name:	LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of milestone.

+ References

No definition available.

+ Details

Name:	LIXT_PercentageOfMilestone
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of proceeds agree to pay under agreement

+ References

No definition available.

+ Details

Name:	LIXT_PercentageOfProceedsAgreeToPayUnderAgreements
Namespace Prefix:	LIXT_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reimbursement expense.

+ References

No definition available.

+ Details

Name:	LIXT_ReimbursementExpense
Namespace Prefix:	LIXT_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for employee benefit and equity-based compensation.

+ References

No definition available.

+ Details

Name:	us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of the nature and terms of commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.

+ References

No definition available.

+ Details

Name:	us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MaterialTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_INSERMMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=LIXT_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=LIXT_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=LIXT_FirstFourYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_Dr.JohnKovachMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_MasterServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_FoundationForAngelmanSyndromeTherapyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=LIXT_ServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=LIXT_IRTHCommunicationsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details Narrative) - USD ($)												1 Months Ended	2 Months Ended	3 Months Ended		6 Months Ended
	May 02, 2021	Feb. 26, 2021	Dec. 21, 2020	Aug. 12, 2020	Feb. 18, 2020	Sep. 12, 2018	Aug. 20, 2018	Mar. 22, 2018	Sep. 14, 2015	Dec. 24, 2013	Dec. 24, 2013	Apr. 30, 2020	Aug. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Loss Contingencies [Line Items]
Research and development costs														$ 262,415	$ 117,946	$ 705,941	$ 212,618
General and administrative costs														1,470,180	255,443	2,751,834	547,928
NDA Consulting Corp [Member]
Loss Contingencies [Line Items]
Agreement term										one-year periods
Consulting and advisory fee											$ 4,000			4,000	4,000	8,000	8,000
City of Hope [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														324,000		324,000
City of Hope [Member] \| Health Care, Patient Service [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														800,000		800,000
Collaboration Agreement [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment		$ 24,171			$ 87,471									0	43,411	24,171	43,411
Research and development costs																155,053
Collaboration Agreement [Member] \| GEIS [Member].
Loss Contingencies [Line Items]
Advance amount related to milestone payment					$ 43,411
Aggregate commitments expected														5,193,000		5,193,000
Collaboration Agreement [Member] \| BioPharmaWorks LLC [Member].
Loss Contingencies [Line Items]
Consulting and advisory fee									$ 10,000
Reimbursed expense														30,000	30,000	60,000	60,000
Collaboration Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment														10,309	11,698	17,693	25,364
Research and development costs																$ 103,927
Clinical Trial Agreement [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected, description																The Company’s aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,798,000 as of June 30, 2021, consisting of approximately $5,193,000 relating to the GEIS clinical trial and approximately $605,000 relating to the Moffit clinical trial, which are expected to be incurred over approximately the next five years through December 31, 2025.
Aggregate commitments expected														5,798,000		$ 5,798,000
Clinical Trial Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														605,000		605,000
Clinical Trial Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment														69,001		309,509
Research and development costs																309,509
Aggregate commitments expected														2,433,000		2,433,000
Other Clinical Agreements [Member]
Loss Contingencies [Line Items]
Aggregate commitments expected														371,000		371,000
Other Clinical Agreements [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Research and development costs																737,000
Work Order Agreement [Member]
Loss Contingencies [Line Items]
Research and development costs																90,636
Aggregate commitments expected														873,000		873,000
Work Order Agreement [Member] \| City of Hope [Member]
Loss Contingencies [Line Items]
Advance amount related to milestone payment														10,773		14,313
Aggregate commitments expected														14,313		14,313
Work Order Agreement [Member] \| Theradex Systems, Inc. [Member]
Loss Contingencies [Line Items]
Research and development costs						$ 954,000								7,540	$ 5,790	8,481	11,476
Material Transfer Agreement [Member] \| INSERM [Member] \| Maximum [Member] \| Development Milestones [Member]
Loss Contingencies [Line Items]
Milestone payments								$ 1,750,000
Material Transfer Agreement [Member] \| INSERM [Member] \| Maximum [Member] \| Commercial Milestones [Member]
Loss Contingencies [Line Items]
Milestone payments								$ 6,500,000
Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Amount charges to operations												$ 6,233		6,233		12,397	$ 12,398
Exclusive License Agreement [Member] \| First Four Years [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties																50,000
Exclusive License Agreement [Member] \| Five Years And Thereafter [Member]
Loss Contingencies [Line Items]
Minimum payments for royalties																100,000
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Loss Contingencies [Line Items]
Non-refundable license issue fee							$ 25,000
Annual license maintenance fee							25,000
Payments on non-refundable milestone							$ 1,897,000
Percentage of milestone							40.00%
Employment Agreement [Member] \| Dr. John Kovach [Member]
Loss Contingencies [Line Items]
Annual salary													$ 640,000
Employment Agreement [Member] \| Dr.James [Member]
Loss Contingencies [Line Items]
Annual compensation	$ 775,000
Master Service Agreement [Member] \| Foundation for Angelman Syndrome Therapy [Member]
Loss Contingencies [Line Items]
Percentage of proceeds agree to pay under agreement				5.00%
Maximum amount received under agreement				$ 250,000
Service Agreement [Member] \| IRTH Communications, LLC [Member]
Loss Contingencies [Line Items]
Consulting and advisory fee			$ 7,500
Stock options grant date fair value			$ 100,000
General and administrative costs														$ 22,500		$ 45,000